Zydus Lifesciences Ltd.

₹913.05

-1.6 (-0.2%)

ZYDUSLIFE Share Price

Pharmaceuticals & Biotechnology

As on March 6, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 91,623 Cr

P/E Ratio20.3

Dividend Yield1.2 %

Trendline Performance

We are partnered with TradingView to provide dynamic charts and powerful tools for market analysis.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	910.64	Bullish
10-DMA	912.39	Bullish
20-DMA	908.81	Bullish
50-DMA	902.48	Bullish
100-DMA	926.59	Bearish
200-DMA	953.17	Bearish

Historical Performance

1 Year

0.6%

3 Years

91.8%

5 Years

106.5%

10 Years

170.2%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	2,32,415	1,95,474	1,72,374	1,51,099	1,44,035
Total Expenditure	1,63,480	1,42,484	1,36,655	1,19,352	1,10,182
Other Income	4,596	3,694	4,746	3,907	750
Operating Profit	73,531	56,684	40,465	35,654	34,603
Interest	1,910	812	1,299	1,270	1,864
Depreciation	9,158	7,641	7,227	7,130	6,696
Profit Before Tax	60,267	48,089	25,897	28,381	23,992
Consolidated Net Profit	45,255	38,595	19,603	44,873	21,336
Adjusted EPS	45	38	19	44	21

Compounded Sales Growth

10 Years:21.9

5 Years:10.3

3 Years:9

TTM:3.5

Compounded Profit Growth

10 Years:31.5

5 Years:30.9

3 Years:0.2

TTM:3.2

Stock Price CAGR

10 Years:10.5

5 Years:15.4

3 Years:24.6

TTM:1.4

Return on Equity

10 Years:18.9

5 Years:20.8

3 Years:19.4

last year:45

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	1,006	1,006	1,012	1,024	1,024
Total Reserves	2,38,525	1,97,289	1,74,146	1,68,972	1,28,899
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	-5,421	1,931	-7,250	-1,936	194
Other Current Liabilities	24,992	16,776	17,985	19,675	21,662
Short Term Borrowings	31,695	7,686	10,810	33,141	30,709
Total Liabilities	3,48,579	2,76,366	2,44,940	2,66,996	2,28,103
Capital Work in Progress	13,179	11,115	11,302	6,610	7,832
Long Term Loans & Advances	4,001	3,445	3,587	3,693	3,233
Currents Investments	48,511	2,525	6,193	23,532	1,989
Short Term Loans and Advances	7,173	7,359	7,117	13,455	10,030
Total Current Assets	1,70,461	1,14,198	1,00,082	1,20,952	87,160
Total Assets	3,48,579	2,76,366	2,44,940	2,66,996	2,28,103
Adjusted Book Value	238	197	173	166	127

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 20.3, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 24.6%, indicating sustained price appreciation.
The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹73531 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹232415 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1021651.6

No. of Shares: 1119 (Approx)

Performance:2.2%

P/L: ₹21651.6

NIFTY Performance: 8.4%

1 day Top Gainers